FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3190999719> ?p ?o ?g. }

• W3190999719 abstract "You have accessJournal of UrologyProstate Cancer: Detection & Screening V (PD50)1 Sep 2021PD50-05 MRI-GUIDED BIOPSY AND THE TRANSFORMATION OF PROSTATE CANCER Wayne Brisbane, Elizabeth Tran, Samantha Gonzalez, Merdie Delfin, Ely Felker, Anthony Sisk, Lorna Kwon, Adam Kinnaird, and Leonard Marks Wayne BrisbaneWayne Brisbane More articles by this author , Elizabeth TranElizabeth Tran More articles by this author , Samantha GonzalezSamantha Gonzalez More articles by this author , Merdie DelfinMerdie Delfin More articles by this author , Ely FelkerEly Felker More articles by this author , Anthony SiskAnthony Sisk More articles by this author , Lorna KwonLorna Kwon More articles by this author , Adam KinnairdAdam Kinnaird More articles by this author , and Leonard MarksLeonard Marks More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002072.05AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: MRI-guided prostate biopsy (MRGB) is rapidly replacing ultrasound-guided biopsy (USGB). As a result, a transformation has occurred in prostate cancer (PCa) detection rate (CDR) and grade of cancer detected; management of PCa is likely to change. The contrast of current (MRGB) and previous (USGB) biopsy findings is reported here. METHODS: Study material were data from all men undergoing MRGB at UCLA, 2010-2020; biopsy was part of a protocol-mandated, IRB-approved registry (N=2971 unique patients; first biopsy = 929, prior biopsy= 2042). Comparator data were from 16,172 men undergoing USGB prior to 2014 (Epstein, Eur.Urol., 2016). Further comparison was made between MRGB results obtained early (2010-2015) and late (2016-2020) in the present series. MRGB was by a single operator using MRI/US fusion (Artemis); image interpretation was by experienced MRI radiologists; biopsy sampling was targeted and systematic; biopsy cores were each reported separately by a GU pathologist. MRI grading was by a Likert scale early-on and PIRADS v2 after 2015; the two are closely correlated. Clinically-significant PCa (csPCa) is defined here as >GG2. RESULTS: With advent of MRGB, CDR increased and GG2 tumors became the most common cancer found; with USGB, insignificant tumors were the commonest finding (Fig. 1). Among men undergoing MRGB, CDR of csPCa was directly related to MRI grade (Fig. 2). Aggressive tumors ( >GG4) were found in only 3% of men with MRI grade <2, but in 36% of men with MRI grade 4 and 5. Insignificant tumors (GG <1) were found in 80% of men with MRI grade <2, but only 11% of men with MRI grade of 5. If biopsy were foregone in men with negative MRI, overall CDR of csPCA was 58% but some csPCa (?20%) would have been missed. CDR was similar between early and late MRGB series. CONCLUSIONS: With MRGB, CDR of csPCa has improved dramatically, and Intermediate-risk PCa has become the commonest cancer found. These voluminous data, obtained prospectively, may be useful in patient counseling and may impact consideration of new treatments. Source of Funding: R01CA195505 and R01CA158627 © 2021 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 206Issue Supplement 3September 2021Page: e853-e853 Advertisement Copyright & Permissions© 2021 by American Urological Association Education and Research, Inc.MetricsAuthor Information Wayne Brisbane More articles by this author Elizabeth Tran More articles by this author Samantha Gonzalez More articles by this author Merdie Delfin More articles by this author Ely Felker More articles by this author Anthony Sisk More articles by this author Lorna Kwon More articles by this author Adam Kinnaird More articles by this author Leonard Marks More articles by this author Expand All Advertisement Loading ..." @default.
• W3190999719 created "2021-08-16" @default.
• W3190999719 creator A5003945364 @default.
• W3190999719 creator A5025958936 @default.
• W3190999719 creator A5027579483 @default.
• W3190999719 creator A5028893537 @default.
• W3190999719 creator A5037769555 @default.
• W3190999719 creator A5051647634 @default.
• W3190999719 creator A5053759649 @default.
• W3190999719 creator A5068459370 @default.
• W3190999719 creator A5069573678 @default.
• W3190999719 date "2021-09-01" @default.
• W3190999719 modified "2023-10-14" @default.
• W3190999719 title "PD50-05 MRI-GUIDED BIOPSY AND THE TRANSFORMATION OF PROSTATE CANCER" @default.
• W3190999719 doi "https://doi.org/10.1097/ju.0000000000002072.05" @default.
• W3190999719 hasPublicationYear "2021" @default.
• W3190999719 type Work @default.
• W3190999719 sameAs 3190999719 @default.
• W3190999719 citedByCount "0" @default.
• W3190999719 crossrefType "journal-article" @default.
• W3190999719 hasAuthorship W3190999719A5003945364 @default.
• W3190999719 hasAuthorship W3190999719A5025958936 @default.
• W3190999719 hasAuthorship W3190999719A5027579483 @default.
• W3190999719 hasAuthorship W3190999719A5028893537 @default.
• W3190999719 hasAuthorship W3190999719A5037769555 @default.
• W3190999719 hasAuthorship W3190999719A5051647634 @default.
• W3190999719 hasAuthorship W3190999719A5053759649 @default.
• W3190999719 hasAuthorship W3190999719A5068459370 @default.
• W3190999719 hasAuthorship W3190999719A5069573678 @default.
• W3190999719 hasBestOaLocation W31909997191 @default.
• W3190999719 hasConcept C121608353 @default.
• W3190999719 hasConcept C126322002 @default.
• W3190999719 hasConcept C126838900 @default.
• W3190999719 hasConcept C2775934546 @default.
• W3190999719 hasConcept C2780192828 @default.
• W3190999719 hasConcept C2781217009 @default.
• W3190999719 hasConcept C2985322473 @default.
• W3190999719 hasConcept C61434518 @default.
• W3190999719 hasConcept C71924100 @default.
• W3190999719 hasConceptScore W3190999719C121608353 @default.
• W3190999719 hasConceptScore W3190999719C126322002 @default.
• W3190999719 hasConceptScore W3190999719C126838900 @default.
• W3190999719 hasConceptScore W3190999719C2775934546 @default.
• W3190999719 hasConceptScore W3190999719C2780192828 @default.
• W3190999719 hasConceptScore W3190999719C2781217009 @default.
• W3190999719 hasConceptScore W3190999719C2985322473 @default.
• W3190999719 hasConceptScore W3190999719C61434518 @default.
• W3190999719 hasConceptScore W3190999719C71924100 @default.
• W3190999719 hasIssue "Supplement 3" @default.
• W3190999719 hasLocation W31909997191 @default.
• W3190999719 hasOpenAccess W3190999719 @default.
• W3190999719 hasPrimaryLocation W31909997191 @default.
• W3190999719 hasRelatedWork W1979374145 @default.
• W3190999719 hasRelatedWork W2001634716 @default.
• W3190999719 hasRelatedWork W2023738390 @default.
• W3190999719 hasRelatedWork W2042932359 @default.
• W3190999719 hasRelatedWork W2065107601 @default.
• W3190999719 hasRelatedWork W2102167265 @default.
• W3190999719 hasRelatedWork W2108412422 @default.
• W3190999719 hasRelatedWork W2991668861 @default.
• W3190999719 hasRelatedWork W4308649819 @default.
• W3190999719 hasRelatedWork W1542377797 @default.
• W3190999719 hasVolume "206" @default.
• W3190999719 isParatext "false" @default.
• W3190999719 isRetracted "false" @default.
• W3190999719 magId "3190999719" @default.
• W3190999719 workType "article" @default.